+91-8668442535

Biosimulation Market By Software Type (PK/PD Modeling And Simulation, Molecular Modeling And Simulation, PBPK Modeling And Simulation, Toxicity Prediction, Trial Design), By Application (Drug Development, Drug Discovery) - Growth, Future Prospects, Competitive Analysis And Forecast 2017 - 2025

The report titled "Global Biosimulation Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall biosimulation market along with the market size and estimates for the duration of 2015–2025. The said research study covers an in-depth analysis of biosimulation market segments based on software type, application, and different geographies further segmented by countries. Biosimulation techniques are the newest additions to the drug development industry, which are based on the simulation of biological processes via computer programs.

This technique is widely used to predict the path of drug development and has proven beneficial in reducing patient numbers, time, and cost incurred in the entire drug development process, thus proving beneficial for the pharmaceutical industry's overall growth. Owing to the aforementioned benefits and an increase in awareness, demand, and adoption of biosimulation, this market is presumed to have increased growth in the forecasted period of 2017–2025.

For the purpose of this study, the global biosimulation market is segmented as follows:

By Software Type

  • PK/PD Modeling and Simulation Software
  • Molecular Modeling and Simulation Software
  • PBPK Modeling and Simulation Software
  • Toxicity Prediction Software
  • Trial Design Software
  • Other Software's

By Application

  • Drug development
  • Preclinical testing
  • Clinical trials
  • Drug discovery
  • Lead Analysis (Identification and Optimization)
  • Target Analysis (Identification and Optimization)
  • Others

Market estimates and forecasts for these segments are provided in US$ Mn, along with the respective compounded annual growth rates (CAGRs) for the period 2017-2025, with 2016 as the base year.

The geographical segmentation of the global biosimulation market comprised regions such as North America, Europe, Asia-Pacific, Latin America & the Middle East, and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. The market size and forecast for these segments during 2015–2025 and their CAGRs for the period 2017–2025 are provided in this report.

The biosimulation market is observed as the most diversified and competitive market, comprising a large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Certara USA, Inc., Simulation Plus, Inc., Dassault Systems SA, Schrodinger, Inc., Advanced Chemistry Development, Inc., Chemical Computing Group, Inc., Physiomics PLC, Entelos, Inc., Rhenovia Pharma Ltd., Genedata AG, Evidera, Inc., In Silico Biosciences, Inc., Oxford Drug Design, Insilico Biotechnology AG, Leadinvent Technologies Pvt. Ltd., and Leadscope, Inc.

Based on the type of software, the global biosimulation market is segmented as follows:

  • PK/PD Modeling and Simulation
  • Molecular Modeling and Simulation
  • PBPK modeling and simulation
  • Toxicity Prediction
  • Trial Design
  • Others.

Within this segment, there is a highly consolidated market share, as each and every piece of software would be used during the course of drug development. Each modeling and simulation software is required to predict each stage of drug development. These software programs would determine the course of a clinical trial and assess its success rate. Because of its widely used applications, such as dosage design prior to a clinical trial, pharmacokinetic profiling of a drug, or the success rate of drug administration on treatment outcomes, PK/PD modeling and simulation software has a marginally higher market share than molecular modeling and simulation software.

The global biosimulation market is divided into the following segments based on application:

Drug development

  • Preclinical testing
  • Clinical trials

Drug discovery

  • Lead Analysis (Identification and Optimization)
  • Target Analysis (Identification and Optimization)
  • Others

The drug development segment encapsulates a larger share of the biosimulation market. This dominance is attributed to the increase in the need for a reduction in adverse effects associated with the current drugs available for treatment, which is propelling the demand for in silico systems to aid in the development of improved molecules. The increased demand is also due to the significant increase in success rates of computer-based modeling in drug development.

The drug discovery segment is also expected to grow in the forecast period of 2017–2025 owing to growing awareness of the benefits of biosimulation, such as bridging the gaps that hinder the drug discovery process, which would enable lowering drug failure rates. The demand for biosimulation in drug discovery would also rise in the forecast period as there would be an increased demand for personalized medicines, which would require lead and target identification and optimization.

For the purpose of this study, the biosimulation market is categorized into three segments:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Biosimulation provides simulation of biological systems, thus rendering it most beneficial in the clinical trial development process and preventing the risks of drug failure. For the purpose of this study, the global biosimulation market is segmented into six regional markets: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America had the largest share of the biosimulation market among the aforementioned regions.

The major factors that drive this predominance in the North American market are the following: an increase in drug development initiations; stringent regulatory policies ensuring patient safety and efficacy standards, thus raising the demand to pre-analyze the success rate of the molecule before entering clinical trials; a rise in the number of strategic collaborations between pharmaceutical industries and research institutes; and in silico developers for simulation-based drug development.

Asia-Pacific is projected to show positive growth in the biosimulation market during the forecast period, 2017–2025. The drivers propelling this market are the increasing presence of CROs, the development of healthcare infrastructure, the penetration of healthcare IT, and an extensive initiation of research and development activities.

Frequently Asked Question:

The market for Biosimulation Market is expected to reach USD$ 4.12 Bn in 2025.

The Biosimulation Market is expected to see significant CAGR growth over the coming years, at 14.8 %.

The report is forecasted to 2017-2025.

The base year of this report is 2016.

Dassault Systems SA, Schrodinger, Inc., Advanced Chemistry Development, Inc., Chemical Computing Group, Inc., Physiomics PLC, Entelos, Inc., Rhenovia Pharma Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Nov 2017
Category:  Pharmaceuticals
Report ID:   58787
Report Format:   PDF
Pages:   120
Rating:    4.8 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support